Sorafenib-Induced Acute Pancreatitis

  • Hamid Saadati Yale University School of Medicine. New Haven, CT, USA
  • Muhammad Wasif Saif Yale University School of Medicine. New Haven, CT, USA
Keywords: Carcinoma, Hepatocellular, Pancreatitis, sorafenib


No abstract available.

Image: Sorafenib BRAF labeled (Author: Nhevitt; Wikimedia Commons)


Download data is not yet available.


Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90. [PMID 18650514]

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-12. [PMID 16636341]

Amar S, Wu KJ, Tan WW. Sorafenib-induced pancreatitis. Mayo Clin Proc 2007; 82:521. [PMID 17418082]

Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 2007; 100:909-11. [PMID 17902294]

Banks PA, Freeman ML, Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101:2379-400. [PMID 17032204]

Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5:648-61. [PMID 17395548]

ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy. Am J Health Syst Pharm 1995; 52:417-9. [PMID 7757870]

National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute 2009. (

Bayer AG. Leverkusen, Germany. Nevaxar (sorafenib). Highlights of prescribing information. (

Sorafenib BRAF labeled
How to Cite
SaadatiH., & SaifM. (2010). Sorafenib-Induced Acute Pancreatitis. JOP. Journal of the Pancreas, 11(3), 283-284.

Most read articles by the same author(s)